HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
24:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
Diuretic therapy has its place in reducing  signs and :@0.090476:0.084931:0.485158:0.084931:0.485158:0.069149:0.090476:0.069149:0.011249:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.006516:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.006516:0.009223:0.010326:0.005866:0.006516:0.003024:0.005125:0.005866:0.006516:0.010311:0.003024:0.010326:0.009782:0.009827:0.006516:0.003024:0.009223:0.006516:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.004188:0.002313:0.005866:0.003024:0.010175:0.009223:0.005866:0.006516:0.010326:0.009223:0.010357:0.004188
symptoms of heart failure, but little data exist to support :@0.076189:0.099098:0.485143:0.099098:0.485143:0.083315:0.076189:0.083315:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.004158:0.009903:0.004747:0.004143:0.009223:0.009827:0.010326:0.004551:0.005125:0.004143:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004143:0.010311:0.009192:0.005125:0.004143:0.003024:0.003024:0.005125:0.005125:0.003024:0.009827:0.004158:0.010357:0.010326:0.005125:0.010326:0.004158:0.009827:0.007257:0.003024:0.005866:0.005125:0.004158:0.005125:0.009903:0.004143:0.005866:0.009192:0.010311:0.010311:0.009903:0.004551:0.005125:0.004188
mortality benefit. :@0.076189:0.113264:0.203793:0.113264:0.203793:0.097481:0.076189:0.097481:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188:0.004188
Ivabradine has been shown to improve clinical out-:@0.090476:0.127430:0.480955:0.127430:0.480955:0.111647:0.090476:0.111647:0.003417:0.008376:0.010326:0.010311:0.004551:0.010326:0.010357:0.003024:0.009223:0.009827:0.006244:0.009223:0.010326:0.005866:0.006244:0.010311:0.009827:0.009827:0.009223:0.006244:0.005866:0.009223:0.009903:0.012564:0.009223:0.006244:0.005125:0.009903:0.006244:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.006244:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.006259:0.009903:0.009192:0.005110:0.005020
comes and should be considered in patients with a rest-:@0.076189:0.141596:0.480971:0.141596:0.480971:0.125814:0.076189:0.125814:0.009782:0.009903:0.014182:0.009827:0.005866:0.003674:0.010326:0.009223:0.010357:0.003689:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003689:0.010311:0.009827:0.003689:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.003674:0.003024:0.009223:0.003689:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003689:0.012564:0.003024:0.005125:0.009223:0.003689:0.010326:0.003689:0.004551:0.009827:0.005866:0.005125:0.005020
ing tachycardia, despite the maximally tolerated beta :@0.076189:0.155763:0.485128:0.155763:0.485128:0.139980:0.076189:0.139980:0.003024:0.009223:0.010175:0.005261:0.005125:0.010326:0.009782:0.009223:0.008104:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.004188:0.005261:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.005277:0.005125:0.009223:0.009827:0.005261:0.014182:0.010326:0.007257:0.003024:0.014182:0.010326:0.003024:0.003024:0.008104:0.005277:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.005261:0.010311:0.009827:0.005125:0.010326:0.004188
blockade. :@0.076189:0.169929:0.155684:0.169929:0.155684:0.154146:0.076189:0.154146:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.004188:0.004188
Angiotensin-converting enzyme inhibitors:@0.076190:0.201202:0.412505:0.201202:0.412505:0.182871:0.076190:0.182871:0.012431:0.010079:0.011087:0.004032:0.010751:0.005040:0.010751:0.010079:0.007392:0.004032:0.010079:0.007056:0.010751:0.010751:0.010079:0.009407:0.010751:0.005376:0.005040:0.004032:0.010079:0.011087:0.004704:0.010751:0.010079:0.007728:0.009743:0.015791:0.010751:0.004704:0.004032:0.010079:0.010079:0.004032:0.011087:0.004032:0.005040:0.010751:0.005376:0.007392
Data show  that  ACE  inhibitors  reduce  morbidity and :@0.076190:0.217546:0.485115:0.217546:0.485115:0.201763:0.076190:0.201763:0.011249:0.010326:0.005125:0.010326:0.007650:0.005866:0.009223:0.009903:0.012564:0.004188:0.003447:0.005125:0.009223:0.010326:0.005125:0.004188:0.003447:0.011188:0.012292:0.008104:0.004188:0.003447:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.003447:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004188:0.003447:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.007650:0.010326:0.009223:0.010357:0.004188
mortality in patients with heart failure with reduced ejec-:@0.076190:0.231712:0.480942:0.231712:0.480942:0.215929:0.076190:0.215929:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.003160:0.003024:0.009223:0.003160:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003160:0.012564:0.003024:0.005125:0.009223:0.003160:0.009223:0.009827:0.010326:0.004551:0.005125:0.003160:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.003160:0.012564:0.003024:0.005125:0.009223:0.003160:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.003160:0.009827:0.003069:0.009827:0.009782:0.005020
tion fraction. These agents inhibit the renin-angiotensin-:@0.076190:0.245878:0.480972:0.245878:0.480972:0.230096:0.076190:0.230096:0.005125:0.003024:0.009903:0.009223:0.004490:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004490:0.006441:0.009223:0.009827:0.005866:0.009827:0.004490:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004490:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.004505:0.005125:0.009223:0.009827:0.004490:0.004551:0.009827:0.009223:0.003024:0.009223:0.005020:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005020
aldosterone  system  (RAAs),  and it is recommended :@0.076190:0.260044:0.485145:0.260044:0.485145:0.244262:0.076190:0.244262:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.009223:0.009827:0.004188:0.004883:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.004188:0.004883:0.005579:0.009177:0.011188:0.011188:0.007529:0.005579:0.004188:0.004188:0.004883:0.010326:0.009223:0.010357:0.009087:0.003024:0.005125:0.009087:0.003024:0.005866:0.009087:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188
that they are titrated to the maximum tolerated doses :@0.076190:0.274211:0.485130:0.274211:0.485130:0.258428:0.076190:0.258428:0.005125:0.009223:0.010326:0.005125:0.005382:0.005125:0.009223:0.009827:0.008104:0.005382:0.010326:0.004551:0.009827:0.005382:0.005125:0.003024:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.005382:0.005125:0.009903:0.005382:0.005125:0.009223:0.009827:0.005382:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.005397:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.005382:0.010357:0.009903:0.005866:0.009827:0.005866:0.004188
to achieve the desired therapeutic effect. Angio-oede-:@0.076190:0.288377:0.480957:0.288377:0.480957:0.272594:0.076190:0.272594:0.005125:0.009903:0.003886:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.003901:0.005125:0.009223:0.009827:0.003886:0.010357:0.009827:0.005866:0.003024:0.004551:0.009827:0.010357:0.003901:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.009827:0.009192:0.005125:0.003024:0.009782:0.003886:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.003886:0.011188:0.009223:0.010175:0.003024:0.009903:0.005020:0.009903:0.009827:0.010357:0.009827:0.005020
ma, renal dysfunction and hypotension may limit tole-:@0.076190:0.302543:0.480957:0.302543:0.480957:0.286761:0.076190:0.286761:0.014182:0.010326:0.004188:0.005866:0.004551:0.009827:0.009223:0.010326:0.003024:0.005866:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.010326:0.009223:0.010357:0.005866:0.009223:0.008104:0.010311:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.005851:0.014182:0.010326:0.008104:0.005866:0.003024:0.003024:0.014182:0.003024:0.005125:0.005866:0.005125:0.009903:0.003024:0.009827:0.005020
rance  and uptitration.  Asymptomatic patients should :@0.076190:0.316709:0.485145:0.316709:0.485145:0.300927:0.076190:0.300927:0.004551:0.010326:0.009223:0.009782:0.009827:0.004188:0.003508:0.010326:0.009223:0.010357:0.007711:0.009192:0.010311:0.005125:0.003024:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003508:0.011188:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.010326:0.005125:0.003024:0.009782:0.007711:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007711:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
also be placed on ACE inhibitor therapy to reduce the :@0.076190:0.330876:0.485130:0.330876:0.485130:0.315093:0.076190:0.315093:0.010326:0.003024:0.005866:0.009903:0.004838:0.010311:0.009827:0.004838:0.010311:0.003024:0.010326:0.009782:0.009827:0.010357:0.004838:0.009903:0.009223:0.004838:0.011188:0.012292:0.008104:0.004838:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.004838:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004838:0.005125:0.009903:0.004838:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004838:0.005125:0.009223:0.009827:0.004188
risk of decompensation, hospitalisation and death. (Tri-:@0.076190:0.345042:0.480942:0.345042:0.480942:0.329259:0.076190:0.329259:0.004551:0.003024:0.005866:0.007590:0.005201:0.009903:0.004747:0.005186:0.010357:0.009827:0.009782:0.009903:0.014182:0.010311:0.009827:0.009223:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.005186:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.005201:0.010326:0.009223:0.010357:0.005186:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.005186:0.005579:0.006441:0.004551:0.003024:0.005020
als  relating to ACE inhibitors include CONsENsUs and :@0.076190:0.359208:0.485130:0.359208:0.485130:0.343426:0.076190:0.343426:0.010326:0.003024:0.005866:0.004188:0.002631:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.006804:0.005125:0.009903:0.006804:0.011188:0.012292:0.008104:0.006804:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006804:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.006804:0.012292:0.013138:0.011188:0.007529:0.008104:0.011188:0.007529:0.009903:0.007529:0.006804:0.010326:0.009223:0.010357:0.004188
sOLVD.):@0.076190:0.373375:0.135472:0.373375:0.135472:0.357592:0.076190:0.357592:0.007529:0.013138:0.006985:0.010614:0.011249:0.004188:0.005579
ACE  inhibitors,  in  addition to  beta-blocker  therapy, :@0.090478:0.387541:0.485130:0.387541:0.485130:0.371758:0.090478:0.371758:0.011188:0.012292:0.008104:0.004188:0.003402:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.004188:0.003402:0.003024:0.009223:0.004188:0.003402:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.007605:0.005125:0.009903:0.004188:0.003402:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.004188:0.003402:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004188
are a class IA-indicated combination – it reduces both :@0.076190:0.401707:0.485160:0.401707:0.485160:0.385924:0.076190:0.385924:0.010326:0.004551:0.009827:0.005065:0.010326:0.005065:0.009782:0.003024:0.010326:0.005866:0.005866:0.005065:0.003417:0.011188:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.005065:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005065:0.007560:0.005065:0.003024:0.005125:0.005065:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005866:0.005065:0.010311:0.009903:0.005125:0.009223:0.004188
hospitalisation and death.:@0.076190:0.415873:0.266811:0.415873:0.266811:0.400091:0.076190:0.400091:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.010326:0.009223:0.010357:0.004188:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188
Angiotensin receptor blockers  CHARM and ValHeFT :@0.090478:0.430040:0.485130:0.430040:0.485130:0.414257:0.090478:0.414257:0.011188:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005927:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.005927:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.007333:0.012292:0.010326:0.011188:0.009177:0.013894:0.005942:0.010326:0.009223:0.010357:0.005942:0.010614:0.010326:0.003024:0.010326:0.009827:0.007333:0.006441:0.004188
(:@0.318806:0.430040:0.324384:0.430040:0.324384:0.414257:0.318806:0.414257:0.005579
trials  are similarly indicated in patients who are intoler-:@0.076190:0.444206:0.480927:0.444206:0.480927:0.428423:0.076190:0.428423:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.005579:0.004899:0.010326:0.004551:0.009827:0.004899:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.003024:0.008104:0.004914:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.004899:0.003024:0.009223:0.004899:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004899:0.012564:0.009223:0.009903:0.004899:0.010326:0.004551:0.009827:0.004899:0.003024:0.009223:0.005125:0.009903:0.003024:0.009827:0.004551:0.005020
):@0.108107:0.444206:0.113686:0.444206:0.113686:0.428423:0.108107:0.428423:0.005579
ant to ACE inhibitors, and have an analogous effect in :@0.076190:0.458372:0.485130:0.458372:0.485130:0.442589:0.076190:0.442589:0.010326:0.009223:0.005125:0.004944:0.005125:0.009903:0.004944:0.011188:0.012292:0.008104:0.004959:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.004959:0.010326:0.009223:0.010357:0.004959:0.009223:0.010326:0.008376:0.009827:0.004944:0.010326:0.009223:0.004959:0.010326:0.009223:0.010326:0.003024:0.009903:0.010175:0.009903:0.009192:0.005866:0.004944:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004944:0.003024:0.009223:0.004188
reducing the negative outcomes in patients with heart :@0.076190:0.472538:0.485145:0.472538:0.485145:0.456756:0.076190:0.456756:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.004959:0.005125:0.009223:0.009827:0.004959:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.008376:0.009827:0.004959:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004959:0.003024:0.009223:0.004959:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004959:0.012564:0.003024:0.005125:0.009223:0.004959:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188
failure.:@0.076190:0.486705:0.125070:0.486705:0.125070:0.470922:0.076190:0.470922:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
ARBs are recommended to replace ACE inhibitors in :@0.090478:0.500871:0.485130:0.500871:0.485130:0.485088:0.090478:0.485088:0.011188:0.009177:0.008678:0.005866:0.005579:0.010326:0.004551:0.009827:0.005579:0.004551:0.009827:0.009782:0.009903:0.014167:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.005579:0.005125:0.009903:0.005579:0.004551:0.009827:0.010311:0.003024:0.010326:0.009782:0.009827:0.005594:0.011188:0.012292:0.008104:0.005579:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005579:0.003024:0.009223:0.004188
patients who are ACE inhibitor-intolerant.  The CHARM :@0.076190:0.515037:0.485145:0.515037:0.485145:0.499255:0.076190:0.499255:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006607:0.012564:0.009223:0.009903:0.006607:0.010326:0.004551:0.009827:0.006607:0.011188:0.012292:0.008104:0.006607:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005020:0.003024:0.009223:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.009223:0.005125:0.004188:0.004188:0.002404:0.006441:0.009223:0.009827:0.006607:0.012292:0.010326:0.011188:0.009177:0.013894:0.004188
trial demonstrated the benefit of candesartan in reduc:@0.076190:0.529203:0.475907:0.529203:0.475907:0.513421:0.076190:0.513421:0.005125:0.004551:0.003024:0.010326:0.003024:0.003946:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.003946:0.005125:0.009223:0.009827:0.003946:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005110:0.003946:0.009903:0.004747:0.003946:0.009782:0.010326:0.009223:0.010357:0.009827:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.003946:0.003024:0.009223:0.003946:0.004551:0.009827:0.010357:0.009192:0.009782
-:@0.475907:0.529203:0.480927:0.529203:0.480927:0.513421:0.475907:0.513421:0.005020
ing  cardiovascular mortality.  Reduced  hospitalisation :@0.076190:0.543370:0.485130:0.543370:0.485130:0.527587:0.076190:0.527587:0.003024:0.009223:0.010175:0.004188:0.004203:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.008406:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004188:0.004203:0.009177:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004188:0.004203:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
was also noted in the ValHeft trial (valsartan). :@0.076190:0.557536:0.410956:0.557536:0.410956:0.541753:0.076190:0.541753:0.012564:0.010326:0.005866:0.004188:0.010326:0.003024:0.005866:0.009903:0.004188:0.009223:0.009903:0.005125:0.009827:0.010357:0.004188:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.010614:0.010326:0.003024:0.010326:0.009827:0.004747:0.005125:0.004188:0.005125:0.004551:0.003024:0.010326:0.003024:0.004188:0.005579:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.005579:0.004188:0.004188
At the Gp level, the combination of ACE inhibitors and :@0.090478:0.571702:0.485145:0.571702:0.485145:0.555920:0.090478:0.555920:0.011188:0.005125:0.003553:0.005125:0.009223:0.009827:0.003553:0.013184:0.008950:0.003553:0.003024:0.009827:0.008376:0.009827:0.003024:0.004188:0.003553:0.005125:0.009223:0.009827:0.003553:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.003553:0.009903:0.004747:0.003553:0.011188:0.012292:0.008104:0.003553:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.003553:0.010326:0.009223:0.010357:0.004188
ARBs is not recommended, although this combination :@0.076190:0.585868:0.485145:0.585868:0.485145:0.570086:0.076190:0.570086:0.011188:0.009177:0.008678:0.005866:0.006184:0.003024:0.005866:0.006184:0.009223:0.009903:0.005125:0.006169:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.006169:0.010326:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.006169:0.005125:0.009223:0.003024:0.005866:0.006184:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
has been used in restricted patients who are unable to :@0.076190:0.600035:0.485115:0.600035:0.485115:0.584252:0.076190:0.584252:0.009223:0.010326:0.005866:0.004717:0.010311:0.009827:0.009827:0.009223:0.004717:0.009192:0.005866:0.009827:0.010357:0.004717:0.003024:0.009223:0.004717:0.004551:0.009827:0.005866:0.005125:0.004551:0.003024:0.009782:0.005125:0.009827:0.010357:0.004717:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004717:0.012564:0.009223:0.009903:0.004717:0.010326:0.004551:0.009827:0.004717:0.009192:0.009223:0.010326:0.010311:0.003024:0.009827:0.004717:0.005125:0.009903:0.004188
use mineralocorticoid antagonists (not recommended :@0.076190:0.614201:0.485145:0.614201:0.485145:0.598418:0.076190:0.598418:0.009192:0.005866:0.009827:0.006093:0.014182:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.006078:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005866:0.006093:0.005579:0.009223:0.009903:0.005125:0.006078:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188
outside of the specialist realm).:@0.076190:0.628367:0.302915:0.628367:0.302915:0.612585:0.076190:0.612585:0.009903:0.009192:0.005125:0.005866:0.003024:0.010357:0.009827:0.004188:0.009903:0.004747:0.004188:0.005125:0.009223:0.009827:0.004188:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.004188:0.004551:0.009827:0.010326:0.003024:0.014182:0.005579:0.004188
beta-blockers:@0.076190:0.659761:0.189751:0.659761:0.189751:0.641429:0.076190:0.641429:0.009743:0.010751:0.005040:0.011087:0.007056:0.011087:0.004032:0.010751:0.010751:0.009743:0.010751:0.005376:0.007392
Beta-blockers reduce mortality  CIBIs-II and COMET trials  :@0.076190:0.676104:0.485130:0.676104:0.485130:0.660322:0.076190:0.660322:0.008678:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.002328:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.002328:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.003719:0.012292:0.003417:0.008678:0.003417:0.007529:0.005020:0.003417:0.003417:0.002343:0.010326:0.009223:0.010357:0.002328:0.012292:0.013138:0.013894:0.008104:0.006441:0.002328:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.005579:0.004188
(:@0.299907:0.676104:0.305486:0.676104:0.305486:0.660322:0.299907:0.660322:0.005579
):@0.475363:0.676104:0.480942:0.676104:0.480942:0.660322:0.475363:0.660322:0.005579
in symptomatic patients with heart failure and reduced :@0.076190:0.690271:0.485130:0.690271:0.485130:0.674488:0.076190:0.674488:0.003024:0.009223:0.004324:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.010326:0.005125:0.003024:0.009782:0.004324:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004324:0.012564:0.003024:0.005125:0.009223:0.004324:0.009223:0.009827:0.010326:0.004551:0.005125:0.004324:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004324:0.010326:0.009223:0.010357:0.004324:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004188
ejection fraction. Beta-blockers are usually withheld in :@0.076190:0.704437:0.485115:0.704437:0.485115:0.688654:0.076190:0.688654:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.006032:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.006032:0.008678:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.006032:0.010326:0.004551:0.009827:0.006032:0.009192:0.005866:0.009192:0.010326:0.003024:0.003024:0.008104:0.006048:0.012564:0.003024:0.005125:0.009223:0.009223:0.009827:0.003024:0.010357:0.006032:0.003024:0.009223:0.004188
the initial phase of stabilisation during heart-failure treat-:@0.076190:0.718603:0.480942:0.718603:0.480942:0.702821:0.076190:0.702821:0.005125:0.009223:0.009827:0.003447:0.003024:0.009223:0.003024:0.005125:0.003024:0.010326:0.003024:0.003462:0.010311:0.009223:0.010326:0.005866:0.009827:0.003462:0.009903:0.004747:0.003447:0.005866:0.005125:0.010326:0.010311:0.003024:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.003462:0.010357:0.009192:0.004551:0.003024:0.009223:0.010175:0.003447:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.003447:0.005125:0.004551:0.009827:0.010326:0.005125:0.005020
ment until adequate diuresis has occurred. Doses may :@0.076190:0.732769:0.485130:0.732769:0.485130:0.716987:0.076190:0.716987:0.014182:0.009827:0.009223:0.005125:0.005277:0.009192:0.009223:0.005125:0.003024:0.003024:0.005277:0.010326:0.010357:0.009827:0.010311:0.009192:0.010326:0.005125:0.009827:0.005277:0.010357:0.003024:0.009192:0.004551:0.009827:0.005866:0.003024:0.005866:0.005292:0.009223:0.010326:0.005866:0.005277:0.009903:0.009782:0.009782:0.009192:0.004551:0.004551:0.009827:0.010357:0.004188:0.005261:0.011249:0.009903:0.005866:0.009827:0.005866:0.005277:0.014182:0.010326:0.008104:0.004188
then be uptitrated slowly to maximum doses, at times :@0.076190:0.746936:0.485115:0.746936:0.485115:0.731153:0.076190:0.731153:0.005125:0.009223:0.009827:0.009223:0.006108:0.010311:0.009827:0.006108:0.009192:0.010311:0.005125:0.003024:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.006108:0.005866:0.003024:0.009903:0.012564:0.003024:0.008104:0.006123:0.005125:0.009903:0.006108:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.006123:0.010357:0.009903:0.005866:0.009827:0.005866:0.004188:0.006108:0.010326:0.005125:0.006108:0.005125:0.003024:0.014182:0.009827:0.005866:0.004188
requiring a few weeks to months to achieve these maxi-:@0.076190:0.761102:0.480927:0.761102:0.480927:0.745319:0.076190:0.745319:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.003024:0.009223:0.010175:0.003780:0.010326:0.003795:0.004747:0.009827:0.012564:0.003795:0.012564:0.009827:0.009827:0.007590:0.005866:0.003795:0.005125:0.009903:0.003780:0.014182:0.009903:0.009223:0.005110:0.009223:0.005866:0.003795:0.005125:0.009903:0.003780:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.003795:0.005125:0.009223:0.009827:0.005866:0.009827:0.003780:0.014182:0.010326:0.007257:0.003024:0.005020
mum  doses.  Common  cardio-selective (B1-selective):@0.076190:0.775268:0.480927:0.775268:0.480927:0.759486:0.076190:0.759486:0.014182:0.009192:0.014182:0.004188:0.004793:0.010357:0.009903:0.005866:0.009827:0.005866:0.004188:0.004188:0.004793:0.012292:0.009903:0.014182:0.014182:0.009903:0.009223:0.004188:0.004793:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.008996:0.005579:0.008678:0.008376:0.005020:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005579
 :@0.480957:0.775268:0.485145:0.775268:0.485145:0.759486:0.480957:0.759486:0.004188
beta-blockers in the south African setting include aten-:@0.076190:0.789435:0.480942:0.789435:0.480942:0.773652:0.076190:0.773652:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004400:0.003024:0.009223:0.004400:0.005125:0.009223:0.009827:0.004385:0.007529:0.009903:0.009192:0.005125:0.009223:0.004385:0.011188:0.004747:0.004536:0.003024:0.009782:0.010326:0.009223:0.004400:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.004385:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004400:0.010326:0.005125:0.009827:0.009223:0.005020
olol, bisoprolol, metoprolol, and carvedilol (alpha- and :@0.076190:0.803601:0.485115:0.803601:0.485115:0.787818:0.076190:0.787818:0.009903:0.003024:0.009903:0.003024:0.004188:0.005156:0.010311:0.003024:0.005866:0.009903:0.010311:0.004551:0.009903:0.003024:0.009903:0.003024:0.004173:0.005156:0.014182:0.009827:0.005125:0.009903:0.010311:0.004551:0.009903:0.003024:0.009903:0.003024:0.004188:0.005140:0.010326:0.009223:0.010357:0.005156:0.009782:0.010326:0.004551:0.008376:0.009827:0.010357:0.003024:0.003024:0.009903:0.003024:0.005171:0.005579:0.010326:0.003024:0.010311:0.009223:0.010326:0.005020:0.005171:0.010326:0.009223:0.010357:0.004188
beta-selective . ACE inhibitors and beta-blockers may :@0.076190:0.817767:0.485115:0.817767:0.485115:0.801984:0.076190:0.801984:0.010311:0.009827:0.005125:0.010326:0.005020:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005579:0.004188:0.006169:0.011188:0.012292:0.008104:0.006169:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006169:0.010326:0.009223:0.010357:0.006169:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.006169:0.014182:0.010326:0.008104:0.004188
):@0.181479:0.817767:0.187058:0.817767:0.187058:0.801984:0.181479:0.801984:0.005579
be started simultaneously, or in a staggered fashion with :@0.076190:0.831933:0.485145:0.831933:0.485145:0.816151:0.076190:0.816151:0.010311:0.009827:0.003492:0.005866:0.005125:0.010326:0.004551:0.005125:0.009827:0.010357:0.003477:0.005866:0.003024:0.014182:0.009192:0.003024:0.005125:0.010326:0.009223:0.009827:0.009903:0.009192:0.005866:0.003024:0.008104:0.004188:0.003492:0.009903:0.004551:0.003477:0.003024:0.009223:0.003492:0.010326:0.003492:0.005866:0.005125:0.010326:0.010175:0.010175:0.009827:0.004551:0.009827:0.010357:0.003477:0.004747:0.010326:0.005866:0.009223:0.003024:0.009903:0.009223:0.003477:0.012564:0.003024:0.005125:0.009223:0.004188
either an ACE inhibitor or a beta-blocker as the initial :@0.076190:0.846100:0.485130:0.846100:0.485130:0.830317:0.076190:0.830317:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.006335:0.010326:0.009223:0.006350:0.011188:0.012292:0.008104:0.006350:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.006350:0.009903:0.004551:0.006335:0.010326:0.006350:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.006350:0.010326:0.005866:0.006350:0.005125:0.009223:0.009827:0.006350:0.003024:0.009223:0.003024:0.005125:0.003024:0.010326:0.003024:0.004188
agent of choice. As mentioned, patients should be clini-:@0.076190:0.860266:0.480942:0.860266:0.480942:0.844483:0.076190:0.844483:0.010326:0.010175:0.009827:0.009223:0.005125:0.003508:0.009903:0.004747:0.003523:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.004188:0.003508:0.011188:0.005866:0.003523:0.014182:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.009827:0.010357:0.004188:0.003508:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003523:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003523:0.010311:0.009827:0.003523:0.009782:0.003024:0.003024:0.009223:0.003024:0.005020
cally  stable with medications uptitrated to maximum :@0.076190:0.874432:0.485130:0.874432:0.485130:0.858649:0.076190:0.858649:0.009782:0.010326:0.003024:0.003024:0.008104:0.004188:0.003341:0.005866:0.005125:0.010326:0.010311:0.003024:0.009827:0.007514:0.012564:0.003024:0.005125:0.009223:0.007514:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.007514:0.009192:0.010311:0.005125:0.003024:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.007514:0.005125:0.009903:0.007514:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.004188
doses if tolerated. :@0.076190:0.888598:0.210599:0.888598:0.210599:0.872816:0.076190:0.872816:0.010357:0.009903:0.005866:0.009827:0.005866:0.004188:0.003024:0.004747:0.004188:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.004188:0.004188
Beta-blockers are especially  useful in the setting of :@0.090478:0.902765:0.485160:0.902765:0.485160:0.886982:0.090478:0.886982:0.008678:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.007363:0.010326:0.004551:0.009827:0.007363:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.004188:0.003190:0.009192:0.005866:0.009827:0.004747:0.009192:0.003024:0.007363:0.003024:0.009223:0.007363:0.005125:0.009223:0.009827:0.007363:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.007363:0.009903:0.004747:0.004188
heart failure with co-existent atrial fibrillation, ischaemic :@0.076190:0.916931:0.485115:0.916931:0.485115:0.901148:0.076190:0.901148:0.009223:0.009827:0.010326:0.004551:0.005125:0.004430:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004430:0.012564:0.003024:0.005125:0.009223:0.004430:0.009782:0.009903:0.005020:0.009827:0.007257:0.003024:0.005866:0.005125:0.009827:0.009223:0.005125:0.004430:0.010326:0.005125:0.004551:0.003024:0.010326:0.003024:0.004430:0.003681:0.003681:0.010311:0.004551:0.003024:0.003024:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004430:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188
heart disease and in the setting of cardiac failure with :@0.076190:0.931097:0.485115:0.931097:0.485115:0.915315:0.076190:0.915315:0.009223:0.009827:0.010326:0.004551:0.005125:0.005382:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005397:0.010326:0.009223:0.010357:0.005382:0.003024:0.009223:0.005382:0.005125:0.009223:0.009827:0.005382:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.005382:0.009903:0.004747:0.005382:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.009782:0.005397:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005382:0.012564:0.003024:0.005125:0.009223:0.004188
other underlying arrhythmias.:@0.076190:0.945263:0.288583:0.945263:0.288583:0.929481:0.076190:0.929481:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188:0.009192:0.009223:0.010357:0.009827:0.004551:0.003024:0.008104:0.003024:0.009223:0.010175:0.004188:0.010326:0.004551:0.004551:0.009223:0.008104:0.005125:0.009223:0.014182:0.003024:0.010326:0.005866:0.004188
mineralocorticoid inhibitors :@0.519047:0.086287:0.744153:0.086287:0.744153:0.067956:0.519047:0.067956:0.015119:0.004032:0.010079:0.010751:0.005376:0.011087:0.004032:0.010751:0.010751:0.010751:0.005376:0.005040:0.004032:0.010751:0.010751:0.004032:0.011087:0.004704:0.004032:0.010079:0.010079:0.004032:0.011087:0.004032:0.005040:0.010751:0.005376:0.007392:0.004704
Mineralocorticoid inhibitor (MRA) therapy (i.e. spirono-:@0.519047:0.102412:0.923784:0.102412:0.923784:0.086629:0.519047:0.086629:0.013894:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.006123:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.006123:0.005579:0.013894:0.009177:0.011188:0.005579:0.006123:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.006123:0.005579:0.003024:0.004188:0.009827:0.004188:0.006123:0.005866:0.010311:0.003024:0.004551:0.009903:0.009223:0.009903:0.005020
lactone and eplerenone) is recommended in all symp-:@0.519047:0.116358:0.923799:0.116358:0.923799:0.100576:0.519047:0.100576:0.003024:0.010326:0.009782:0.005125:0.009903:0.009223:0.009827:0.004778:0.010326:0.009223:0.010357:0.004793:0.009827:0.010311:0.003024:0.009827:0.004551:0.009827:0.009223:0.009903:0.009223:0.009827:0.005579:0.004778:0.003024:0.005866:0.004793:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004778:0.003024:0.009223:0.004793:0.010326:0.003024:0.003024:0.004793:0.005866:0.008104:0.014182:0.010311:0.005020
tomatic patients with heart failure with reduced ejection :@0.519047:0.130305:0.927987:0.130305:0.927987:0.114523:0.519047:0.114523:0.005125:0.009903:0.014182:0.010326:0.005125:0.003024:0.009782:0.003024:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003024:0.012564:0.003024:0.005125:0.009223:0.003024:0.009223:0.009827:0.010326:0.004551:0.005125:0.003024:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.003024:0.012564:0.003024:0.005125:0.009223:0.003024:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.003024:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
fraction (ejection fraction  of less than 35%; NYHA  II+), :@0.519047:0.144252:0.928002:0.144252:0.928002:0.128470:0.519047:0.128470:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.006607:0.005579:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.006607:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.002404:0.009903:0.004747:0.006607:0.003024:0.009827:0.005866:0.005866:0.006607:0.005125:0.009223:0.010326:0.009223:0.006607:0.008376:0.008376:0.011717:0.004188:0.006607:0.011188:0.008950:0.010326:0.011188:0.004188:0.002419:0.003417:0.003417:0.009162:0.005579:0.004188:0.004188
in addition to ACE inhibitors and beta-blockers, to re-:@0.519047:0.158199:0.923784:0.158199:0.923784:0.142417:0.519047:0.142417:0.003024:0.009223:0.006410:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.006410:0.005125:0.009903:0.006410:0.011188:0.012292:0.008104:0.006410:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006410:0.010326:0.009223:0.010357:0.006410:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.006410:0.005125:0.009903:0.006410:0.004551:0.009827:0.005020
duce hospitalisation and mortality. Caution should be :@0.519047:0.172146:0.927987:0.172146:0.927987:0.156363:0.519047:0.156363:0.010357:0.009192:0.009782:0.009827:0.006335:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005881:0.010326:0.005125:0.003024:0.009903:0.009223:0.006335:0.010326:0.009223:0.010357:0.006350:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.006335:0.012292:0.010326:0.009192:0.005125:0.003024:0.009903:0.009223:0.006335:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.006350:0.010311:0.009827:0.004188
exercised  in patients  with hyperkalaemia and those :@0.519047:0.186093:0.928002:0.186093:0.928002:0.170310:0.519047:0.170310:0.009827:0.007257:0.009827:0.004551:0.009782:0.003024:0.005866:0.009827:0.010357:0.004188:0.004626:0.003024:0.009223:0.008830:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004626:0.012564:0.003024:0.005125:0.009223:0.008830:0.009223:0.008104:0.010311:0.009827:0.004551:0.007590:0.010326:0.003024:0.010326:0.009827:0.014182:0.003024:0.010326:0.008830:0.010326:0.009223:0.010357:0.008830:0.005125:0.009223:0.009903:0.005866:0.009827:0.004188
with impaired renal function. potassium levels should be :@0.519047:0.200040:0.928002:0.200040:0.928002:0.184257:0.519047:0.184257:0.012564:0.003024:0.005125:0.009223:0.003961:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.003976:0.004551:0.009827:0.009223:0.010326:0.003024:0.003961:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003976:0.008950:0.009903:0.005125:0.010326:0.005866:0.005866:0.003024:0.009192:0.014182:0.003976:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.003976:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003961:0.010311:0.009827:0.004188
monitored. Gynaecomastia is an important complica-:@0.519047:0.213987:0.923784:0.213987:0.923784:0.198204:0.519047:0.198204:0.014182:0.009903:0.009223:0.003024:0.005125:0.009903:0.004551:0.009827:0.010357:0.004188:0.005927:0.013184:0.008104:0.009223:0.010326:0.009827:0.009782:0.009903:0.014182:0.010326:0.005866:0.005125:0.003024:0.010326:0.005942:0.003024:0.005866:0.005942:0.010326:0.009223:0.005942:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.005942:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005020
tion to discuss with patients because mineralocorticoid :@0.519047:0.227934:0.927987:0.227934:0.927987:0.212151:0.519047:0.212151:0.005125:0.003024:0.009903:0.009223:0.004838:0.005125:0.009903:0.004838:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.004853:0.012564:0.003024:0.005125:0.009223:0.004853:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004853:0.010311:0.009827:0.009782:0.010326:0.009192:0.005866:0.009827:0.004853:0.014182:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.004188
antagonists have an affinity for steroid-binding proteins, :@0.519047:0.241881:0.927987:0.241881:0.927987:0.226098:0.519047:0.226098:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005866:0.004188:0.009223:0.010326:0.008376:0.009827:0.004188:0.010326:0.009223:0.004188:0.010326:0.004747:0.003681:0.003681:0.009223:0.003024:0.005125:0.008104:0.004188:0.004747:0.009903:0.004551:0.004188:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.010357:0.005020:0.010311:0.003024:0.009223:0.010357:0.003024:0.009223:0.010175:0.004188:0.010311:0.004551:0.009903:0.005125:0.009827:0.003024:0.009223:0.005866:0.004188:0.004188
which may affect androgen-, oestrogen- and corticos-:@0.519047:0.255828:0.923829:0.255828:0.923829:0.240045:0.519047:0.240045:0.012564:0.009223:0.003024:0.009782:0.009223:0.004793:0.014182:0.010326:0.008104:0.004793:0.010326:0.004747:0.004747:0.009827:0.009782:0.005125:0.004793:0.010326:0.009223:0.010357:0.004551:0.009903:0.010175:0.009827:0.009223:0.005020:0.004188:0.004778:0.009903:0.009827:0.005866:0.005125:0.004551:0.009903:0.010175:0.009827:0.009223:0.005020:0.004778:0.010326:0.009223:0.010357:0.004793:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.005866:0.005020
teroid-binding. In male subjects, eplerenone has a lesser :@0.519047:0.269774:0.928002:0.269774:0.928002:0.253992:0.519047:0.253992:0.005125:0.009827:0.004551:0.009903:0.003024:0.010357:0.005020:0.010311:0.003024:0.009223:0.010357:0.003024:0.009223:0.010175:0.004188:0.003417:0.003417:0.009223:0.003417:0.014182:0.010326:0.003024:0.009827:0.003432:0.005866:0.009192:0.010311:0.003069:0.009827:0.009782:0.005125:0.005866:0.004188:0.003432:0.009827:0.010311:0.003024:0.009827:0.004551:0.009827:0.009223:0.009903:0.009223:0.009827:0.003417:0.009223:0.010326:0.005866:0.003432:0.010326:0.003417:0.003024:0.009827:0.005866:0.005866:0.009827:0.004551:0.004188
propensity for the development for gynaecomastia,:@0.519047:0.283721:0.899170:0.283721:0.899170:0.267939:0.519047:0.267939:0.010311:0.004551:0.009903:0.010311:0.009827:0.009223:0.005866:0.003024:0.005125:0.008104:0.004188:0.004747:0.009903:0.004551:0.004188:0.005125:0.009223:0.009827:0.004188:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.004188:0.004747:0.009903:0.004551:0.004188:0.010175:0.008104:0.009223:0.010326:0.009827:0.009782:0.009903:0.014182:0.010326:0.005866:0.005125:0.003024:0.010326:0.004188
Studies  related  to  mineralocorticoid  antagonist  effi:@0.533335:0.297668:0.918810:0.297668:0.918810:0.281886:0.533335:0.281886:0.007529:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.003160:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.010357:0.004188:0.003160:0.005125:0.009903:0.004188:0.003145:0.014182:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.004188:0.003160:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004188:0.003160:0.009827:0.004747:0.003681:0.003681
-:@0.918810:0.297668:0.923829:0.297668:0.923829:0.281886:0.918810:0.281886:0.005020
cacy refer to the RALEs trial (NYHA III+) and EMpHAsIs :@0.519047:0.311615:0.927987:0.311615:0.927987:0.295832:0.519047:0.295832:0.009782:0.010326:0.009782:0.008104:0.005775:0.004551:0.009827:0.004747:0.009827:0.004551:0.005775:0.005125:0.009903:0.005775:0.005125:0.009223:0.009827:0.005775:0.009177:0.011188:0.006985:0.008104:0.007529:0.005775:0.005125:0.004551:0.003024:0.010326:0.003024:0.005775:0.005579:0.011188:0.008950:0.010326:0.011188:0.005745:0.003417:0.003417:0.003417:0.009162:0.005579:0.005775:0.010326:0.009223:0.010357:0.005775:0.008104:0.013894:0.008950:0.010326:0.011188:0.007529:0.003417:0.007529:0.004188
trial (NYHA  II+).  patients with ischaemic  heart disease :@0.519047:0.325562:0.927987:0.325562:0.927987:0.309779:0.519047:0.309779:0.005125:0.004551:0.003024:0.010326:0.003024:0.007015:0.005579:0.011188:0.008950:0.010326:0.011188:0.004188:0.002827:0.003417:0.003417:0.009162:0.005579:0.004188:0.004188:0.002827:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007015:0.012564:0.003024:0.005125:0.009223:0.007015:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188:0.002842:0.009223:0.009827:0.010326:0.004551:0.005125:0.007015:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188
and  heart  failure  may  also  benefit  from  the  addition :@0.519047:0.339509:0.927987:0.339509:0.927987:0.323726:0.519047:0.323726:0.010326:0.009223:0.010357:0.004188:0.003160:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.003160:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.003160:0.014182:0.010326:0.008104:0.004188:0.003160:0.010326:0.003024:0.005866:0.009903:0.004188:0.003175:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188:0.003160:0.004747:0.004551:0.009903:0.014182:0.004188:0.003160:0.005125:0.009223:0.009827:0.004188:0.003160:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.004188
of a mineralocorticoid  antagonist.  Mineralocorticoid :@0.519047:0.353456:0.928002:0.353456:0.928002:0.337673:0.519047:0.337673:0.009903:0.004747:0.009646:0.010326:0.009646:0.014182:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.004188:0.005443:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004188:0.004188:0.005443:0.013894:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.004188
antagonists are also of great benefit in the post-ST eleva:@0.519047:0.367403:0.918764:0.367403:0.918764:0.351620:0.519047:0.351620:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005866:0.003039:0.010326:0.004551:0.009827:0.003039:0.010326:0.003024:0.005866:0.009903:0.003054:0.009903:0.004747:0.003039:0.010175:0.004551:0.009827:0.010326:0.005125:0.003039:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.003039:0.003024:0.009223:0.003054:0.005125:0.009223:0.009827:0.003039:0.010311:0.009903:0.005866:0.005125:0.005020:0.007529:0.006441:0.003039:0.009827:0.003024:0.009827:0.008376:0.010326
-:@0.918764:0.367403:0.923784:0.367403:0.923784:0.351620:0.918764:0.351620:0.005020
tion myocardial infarction setting, where the LVEF ≤40%.:@0.519047:0.381350:0.923814:0.381350:0.923814:0.365567:0.519047:0.365567:0.005125:0.003024:0.009903:0.009223:0.004037:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.004037:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004037:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.004188:0.004037:0.012564:0.009223:0.009827:0.004551:0.009827:0.004037:0.005125:0.009223:0.009827:0.004037:0.006985:0.010614:0.008104:0.007333:0.004052:0.008300:0.008376:0.008376:0.011717:0.004188
Angiotensin receptor blocker-neprilysin inhibitors :@0.519047:0.412740:0.921549:0.412740:0.921549:0.394409:0.519047:0.394409:0.012431:0.010079:0.011087:0.004032:0.010751:0.005040:0.010751:0.010079:0.007392:0.004032:0.010079:0.004704:0.005376:0.010751:0.010751:0.010751:0.011087:0.005040:0.010751:0.005376:0.004704:0.011087:0.004032:0.010751:0.010751:0.009743:0.010751:0.005376:0.007056:0.010079:0.010751:0.011087:0.005376:0.004032:0.004032:0.009743:0.007392:0.004032:0.010079:0.004704:0.004032:0.010079:0.010079:0.004032:0.011087:0.004032:0.005040:0.010751:0.005376:0.007392:0.004704
Angiotensin receptor blocker-neprilysin inhibitors (ARNIs) :@0.519047:0.428865:0.928002:0.428865:0.928002:0.413082:0.519047:0.413082:0.011188:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.003402:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.003402:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005020:0.009223:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.003417:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.003417:0.005579:0.011188:0.009177:0.011188:0.003417:0.005866:0.005579:0.004188
constitute a new therapeutic class of drugs acting on :@0.519047:0.442812:0.928002:0.442812:0.928002:0.427029:0.519047:0.427029:0.009782:0.009903:0.009223:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.009827:0.005972:0.010326:0.005987:0.009223:0.009827:0.012564:0.005987:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.009827:0.009192:0.005125:0.003024:0.009767:0.005987:0.009782:0.003024:0.010326:0.005866:0.005866:0.006002:0.009903:0.004747:0.005987:0.010357:0.004551:0.009192:0.010175:0.005866:0.005987:0.010326:0.009782:0.005125:0.003024:0.009223:0.010175:0.005987:0.009903:0.009223:0.004188
the  renin-angiotensin  aldosterone  system (RAAs)  and :@0.519047:0.456759:0.927987:0.456759:0.927987:0.440976:0.519047:0.440976:0.005125:0.009223:0.009827:0.004188:0.003356:0.004551:0.009827:0.009207:0.003024:0.009223:0.005020:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004188:0.003356:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.009223:0.009827:0.004188:0.003356:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.007560:0.005579:0.009177:0.011188:0.011188:0.007529:0.005579:0.004188:0.003356:0.010326:0.009223:0.010357:0.004188
the  natriuretic  peptide system. The  original  molecule, :@0.519047:0.470705:0.928002:0.470705:0.928002:0.454923:0.519047:0.454923:0.005125:0.009223:0.009827:0.004188:0.003009:0.009223:0.010326:0.005125:0.004551:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.004188:0.003009:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.007212:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.004188:0.007212:0.006441:0.009223:0.009827:0.004188:0.003009:0.009903:0.004551:0.003024:0.010175:0.003024:0.009223:0.010326:0.003024:0.004188:0.003009:0.014182:0.009903:0.003024:0.009827:0.009782:0.009192:0.003024:0.009827:0.004188:0.004188
LCZ  696,  now traded as Entresto , is  a composite of :@0.519047:0.484652:0.928000:0.484675:0.928000:0.468892:0.519047:0.468870:0.006985:0.012292:0.007257:0.004188:0.003613:0.008376:0.008376:0.008376:0.004188:0.004188:0.003629:0.009223:0.009903:0.012564:0.007801:0.005125:0.004551:0.010326:0.010357:0.009827:0.010357:0.007801:0.010326:0.005866:0.007801:0.008104:0.009223:0.005125:0.004551:0.009827:0.005866:0.005125:0.009903:0.006545:0.004188:0.007801:0.003024:0.005866:0.004188:0.003629:0.010326:0.007801:0.009782:0.009903:0.014182:0.010311:0.009903:0.005866:0.003024:0.005125:0.009827:0.007801:0.009903:0.004747:-0.228314
®:@0.770062:0.479376:0.776613:0.479376:0.776613:0.470222:0.770062:0.470222:0.006550
valsartan and sacubitril, a neuropeptidase inhibitor :@0.519045:0.498621:0.928000:0.498621:0.928000:0.482839:0.519045:0.482839:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.010780:0.010326:0.009223:0.010357:0.010780:0.005866:0.010326:0.009782:0.009192:0.010311:0.003024:0.005125:0.004551:0.003024:0.003024:0.004188:0.010780:0.010326:0.010780:0.009223:0.009827:0.009192:0.004551:0.009903:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.010326:0.005866:0.009827:0.010780:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.004188
(neprilysin inhibitor).  Neprilysin breaks down BNp (brain :@0.519045:0.512568:0.927999:0.512580:0.927999:0.496797:0.519045:0.496786:0.005579:0.009223:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.005080:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005579:0.004188:0.004867:0.005080:0.011188:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.005080:0.010311:0.004551:0.009827:0.010326:0.007590:0.005866:0.005080:0.010357:0.009903:0.012564:0.009223:0.005080:0.008678:0.011188:0.008950:0.005080:0.005579:0.010311:0.004551:0.010326:0.003024:0.009223:-0.264855
3:@0.663062:0.507281:0.667920:0.507281:0.667920:0.498127:0.663062:0.498127:0.004858
natriuretic protein), potentially decreasing its beneficial :@0.519045:0.526526:0.927984:0.526526:0.927984:0.510744:0.519045:0.510744:0.009223:0.010326:0.005125:0.004551:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.004505:0.010311:0.004551:0.009903:0.005125:0.009827:0.003024:0.009223:0.005579:0.004188:0.004505:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.003024:0.008104:0.004521:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.004521:0.003024:0.005125:0.005866:0.004521:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.004188
effect.  Neprilysin also breaks down angiotensin  I and :@0.519045:0.540473:0.927984:0.540473:0.927984:0.524691:0.519045:0.524691:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.004188:0.003009:0.011188:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.007212:0.010326:0.003024:0.005866:0.009903:0.007212:0.010311:0.004551:0.009827:0.010326:0.007590:0.005866:0.007212:0.010357:0.009903:0.012564:0.009223:0.007212:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004188:0.003024:0.003417:0.007212:0.010326:0.009223:0.010357:0.004188
angiotensin II. By inhibiting neprilysin, angiotensin levels :@0.519045:0.554420:0.927984:0.554420:0.927984:0.538638:0.519045:0.538638:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005231:0.003417:0.003417:0.004188:0.005231:0.008678:0.008104:0.005231:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.003024:0.009223:0.010175:0.005231:0.009223:0.009827:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.004188:0.005231:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005231:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.004188
increase, negating the beneficial effects of an elevated :@0.519045:0.568367:0.927999:0.568367:0.927999:0.552585:0.519045:0.552585:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004188:0.003341:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.009223:0.010175:0.003326:0.005125:0.009223:0.009827:0.003326:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.003341:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.003341:0.009903:0.004747:0.003341:0.010326:0.009223:0.003341:0.009827:0.003024:0.009827:0.008376:0.010326:0.005125:0.009827:0.010357:0.004188
BNp. The addition of valsartan, therefore, inhibits the an-:@0.519045:0.582314:0.923811:0.582314:0.923811:0.566531:0.519045:0.566531:0.008678:0.011188:0.008950:0.004188:0.003704:0.006441:0.009223:0.009827:0.003704:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.003704:0.009903:0.004747:0.003704:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.004188:0.003704:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.004188:0.003689:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.005866:0.003704:0.005125:0.009223:0.009827:0.003704:0.010326:0.009223:0.005020
giotensin 1 receptor (the receptor for angiotensin II), re-:@0.519045:0.596261:0.923811:0.596261:0.923811:0.580478:0.519045:0.580478:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004173:0.008376:0.004173:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004158:0.005579:0.005125:0.009223:0.009827:0.004173:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004158:0.004747:0.009903:0.004551:0.004173:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004173:0.003417:0.003417:0.005579:0.004188:0.004173:0.004551:0.009827:0.005020
sponsible for vasoconstriction, sodium and water reten-:@0.519045:0.610208:0.923811:0.610208:0.923811:0.594425:0.519045:0.594425:0.005866:0.010311:0.009903:0.009223:0.005866:0.003024:0.010311:0.003024:0.009827:0.004445:0.004747:0.009903:0.004551:0.004430:0.008376:0.010326:0.005866:0.009903:0.009782:0.009903:0.009223:0.005866:0.005125:0.004551:0.003024:0.009782:0.005125:0.003024:0.009903:0.009223:0.004173:0.004445:0.005866:0.009903:0.010357:0.003024:0.009192:0.014182:0.004445:0.010326:0.009223:0.010357:0.004445:0.012564:0.010326:0.005125:0.009827:0.004551:0.004430:0.004551:0.009827:0.005125:0.009827:0.009223:0.005020
tion, including myocardial hypertrophy. The beneficial :@0.519045:0.624155:0.927999:0.624155:0.927999:0.608372:0.519045:0.608372:0.005125:0.003024:0.009903:0.009223:0.004188:0.006214:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.006214:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.006229:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.004551:0.009903:0.010311:0.009223:0.008104:0.004188:0.006214:0.006441:0.009223:0.009827:0.006214:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.004188
effects of BNp are then able to take effect, including :@0.519045:0.638102:0.927984:0.638102:0.927984:0.622319:0.519045:0.622319:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.006290:0.009903:0.004747:0.006290:0.008678:0.011188:0.008950:0.006290:0.010326:0.004551:0.009827:0.006290:0.005125:0.009223:0.009827:0.009223:0.006290:0.010326:0.010311:0.003024:0.009827:0.006290:0.005125:0.009903:0.006290:0.005125:0.010326:0.007590:0.009827:0.006290:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.006290:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.004188
potentiating sodium and water loss, reducing aldoster-:@0.519045:0.652049:0.923796:0.652049:0.923796:0.636266:0.519045:0.636266:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.005080:0.005866:0.009903:0.010357:0.003024:0.009192:0.014182:0.005095:0.010326:0.009223:0.010357:0.005095:0.012564:0.010326:0.005125:0.009827:0.004551:0.005095:0.003024:0.009903:0.005866:0.005866:0.004188:0.005095:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.005080:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.005020
one and renin secretion, reducing sympathetic outflow, :@0.519045:0.665995:0.928015:0.665995:0.928015:0.650213:0.519045:0.650213:0.009903:0.009223:0.009827:0.003916:0.010326:0.009223:0.010357:0.003931:0.004551:0.009827:0.009223:0.003024:0.009223:0.003916:0.005866:0.009827:0.009782:0.004551:0.009827:0.005125:0.003024:0.009903:0.009223:0.004188:0.003916:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.003916:0.005866:0.008104:0.014182:0.010311:0.010326:0.005125:0.009223:0.009827:0.005125:0.003024:0.009782:0.003931:0.009903:0.009192:0.005125:0.003666:0.003666:0.009903:0.012564:0.004188:0.004188
decreasing  vasopressin secretion,  and reducting  salt :@0.519045:0.679942:0.927984:0.679942:0.927984:0.664160:0.519045:0.664160:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.004188:0.004173:0.008376:0.010326:0.005866:0.009903:0.010311:0.004551:0.009827:0.005866:0.005866:0.003024:0.009223:0.008376:0.005866:0.009827:0.009782:0.004551:0.009827:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.004173:0.010326:0.009223:0.010357:0.008376:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009223:0.010175:0.004188:0.004173:0.005866:0.010326:0.003024:0.005125:0.004188
appetite and water intake. It also reduces myocardial :@0.519045:0.693889:0.927984:0.693889:0.927984:0.678107:0.519045:0.678107:0.010326:0.010311:0.010311:0.009827:0.005125:0.003024:0.005125:0.009827:0.005518:0.010326:0.009223:0.010357:0.005518:0.012564:0.010326:0.005125:0.009827:0.004551:0.005518:0.003024:0.009223:0.005125:0.010326:0.007590:0.009827:0.004188:0.005518:0.003417:0.005125:0.005518:0.010326:0.003024:0.005866:0.009903:0.005518:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005866:0.005518:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.004188
hypertrophy and fibroblast proliferation, augments va:@0.519045:0.707836:0.918777:0.707836:0.918777:0.692054:0.519045:0.692054:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.004551:0.009903:0.010311:0.009223:0.008104:0.005881:0.010326:0.009223:0.010357:0.005896:0.003681:0.003681:0.010311:0.004551:0.009903:0.010311:0.003024:0.010326:0.005866:0.005125:0.005896:0.010311:0.004551:0.009903:0.003024:0.003024:0.004747:0.009827:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.005896:0.010326:0.009192:0.010175:0.014182:0.009827:0.009223:0.005125:0.005866:0.005896:0.008376:0.010326
-:@0.918777:0.707836:0.923796:0.707836:0.923796:0.692054:0.918777:0.692054:0.005020
sodilatation and reduces systemic vascular resistance. :@0.519045:0.721783:0.927999:0.721783:0.927999:0.706000:0.519045:0.706000:0.005866:0.009903:0.010357:0.003024:0.003024:0.010326:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005881:0.010326:0.009223:0.010357:0.005881:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005866:0.005881:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.005881:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005881:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.004188
The beneficial effects of natriuretic peptides (BNP and :@0.519045:0.735730:0.927999:0.735730:0.927999:0.719947:0.519045:0.719947:0.006441:0.009223:0.009827:0.005609:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.005624:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005609:0.009903:0.004747:0.005609:0.009223:0.010326:0.005125:0.004551:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.005609:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.005866:0.005624:0.005579:0.008678:0.011188:0.008950:0.005609:0.010326:0.009223:0.010357:0.004188
ANp) also reduce pulmonary artery pressure, pulmonary :@0.519045:0.749677:0.927984:0.749677:0.927984:0.733894:0.519045:0.733894:0.011188:0.011188:0.008950:0.005579:0.003477:0.010326:0.003024:0.005866:0.009903:0.003477:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.003492:0.010311:0.009192:0.003024:0.014182:0.009903:0.009223:0.010326:0.004551:0.008104:0.003492:0.010326:0.004551:0.005125:0.009827:0.004551:0.008104:0.003477:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004188:0.003477:0.010311:0.009192:0.003024:0.014182:0.009903:0.009223:0.010326:0.004551:0.008104:0.004188
artery wedge pressure and right atrial pressures. :@0.519045:0.763624:0.872014:0.763624:0.872014:0.747841:0.519045:0.747841:0.010326:0.004551:0.005125:0.009827:0.004551:0.008104:0.004188:0.012564:0.009827:0.010357:0.010175:0.009827:0.004188:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004188:0.010326:0.009223:0.010357:0.004188:0.004551:0.003024:0.010175:0.009223:0.005125:0.004188:0.010326:0.005125:0.004551:0.003024:0.010326:0.003024:0.004188:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.005866:0.004188:0.004188
The  pARADIGM-HF trial  was an active-controlled :@0.533332:0.777571:0.928013:0.777676:0.928013:0.761894:0.533332:0.761788:0.006441:0.009223:0.009827:0.004188:0.005277:0.008950:0.011173:0.009177:0.011188:0.011249:0.003417:0.013184:0.013894:0.005020:0.010326:0.007333:0.009480:0.005125:0.004551:0.003024:0.010326:0.003024:0.012155:0.009480:0.012564:0.010326:0.005866:0.009480:0.010326:0.009223:0.009480:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.005020:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:-0.612020
1,2:@0.708735:0.772378:0.720880:0.772378:0.720880:0.763224:0.708735:0.763224:0.004858:0.002429:0.004858
study that evaluated the superiority of Entresto  versus :@0.519043:0.791623:0.927994:0.791629:0.927994:0.775846:0.519043:0.775841:0.005866:0.005125:0.009192:0.010357:0.008104:0.006032:0.005125:0.009223:0.010326:0.005125:0.003501:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.009827:0.010357:0.006032:0.005125:0.009223:0.009827:0.006032:0.005866:0.009192:0.010311:0.009827:0.004551:0.003024:0.009903:0.004551:0.003024:0.005125:0.008104:0.006032:0.009903:0.004747:0.006032:0.008104:0.009223:0.005125:0.004551:0.009827:0.005866:0.005125:0.009903:0.006534:0.006032:0.008376:0.009827:0.004551:0.005866:0.009192:0.005866:-0.630272
 :@0.593521:0.786330:0.595950:0.786330:0.595950:0.777176:0.593521:0.777176:0.002429
®:@0.867544:0.786330:0.874094:0.786330:0.874094:0.777176:0.867544:0.777176:0.006550
enalapril on  rates of  heart-failure hospitalisation and :@0.519055:0.805576:0.927994:0.805576:0.927994:0.789793:0.519055:0.789793:0.009827:0.009223:0.010326:0.003024:0.010326:0.010311:0.004551:0.003024:0.003024:0.008285:0.009903:0.009223:0.004188:0.004082:0.004551:0.010326:0.005125:0.009827:0.005866:0.008285:0.009903:0.004747:0.004188:0.004082:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.008285:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.008285:0.010326:0.009223:0.010357:0.004188
mortality reduction in patients with chronic HF EF, and :@0.519055:0.819523:0.928024:0.819523:0.928024:0.803740:0.519055:0.803740:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.006032:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.006017:0.003024:0.009223:0.006032:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006032:0.012564:0.003024:0.005125:0.009223:0.006032:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.006017:0.010326:0.007333:0.004551:0.008104:0.007333:0.004188:0.006032:0.010326:0.009223:0.010357:0.004188
r:@0.863723:0.819523:0.868274:0.819523:0.868274:0.803740:0.863723:0.803740:0.004551
provided evidence to support the replacement of ACE :@0.519055:0.833469:0.928009:0.833469:0.928009:0.817687:0.519055:0.817687:0.010311:0.004551:0.009903:0.008376:0.003024:0.010357:0.009827:0.010357:0.004445:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.004445:0.005125:0.009903:0.004445:0.005866:0.009192:0.010311:0.010311:0.009903:0.004551:0.005125:0.004445:0.005125:0.009223:0.009827:0.004445:0.004551:0.009827:0.010311:0.003024:0.010326:0.009782:0.009827:0.014182:0.009827:0.009223:0.005125:0.004445:0.009903:0.004747:0.004445:0.011188:0.012292:0.008104:0.004188
inhibitors or ARBs with Entresto  in the management of :@0.519055:0.847416:0.927996:0.847439:0.927996:0.831656:0.519055:0.831634:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005564:0.009903:0.004551:0.005549:0.011188:0.009177:0.008678:0.005866:0.005564:0.012564:0.003024:0.005125:0.009223:0.005549:0.008104:0.009223:0.005125:0.004551:0.009827:0.005866:0.005125:0.009903:0.006533:0.005549:0.003024:0.009223:0.005564:0.005125:0.009223:0.009827:0.005549:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.005549:0.009903:0.004747:-0.703357
®:@0.741558:0.842140:0.748109:0.842140:0.748109:0.832986:0.741558:0.832986:0.006550
chronic HF EF. seventy per cent of the study population :@0.519041:0.861386:0.927996:0.861386:0.927996:0.845603:0.519041:0.845603:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.004112:0.010326:0.007333:0.004551:0.008104:0.007333:0.004188:0.004127:0.007529:0.009827:0.008376:0.009827:0.009223:0.005125:0.008104:0.004127:0.010311:0.009827:0.004551:0.004127:0.009782:0.009827:0.009223:0.005125:0.004112:0.009903:0.004747:0.004127:0.005125:0.009223:0.009827:0.004112:0.005866:0.005125:0.009192:0.010357:0.008104:0.004127:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
r:@0.596299:0.861386:0.600850:0.861386:0.600850:0.845603:0.596299:0.845603:0.004551
were NYHA Class II (slight limitation of physical activity – :@0.519041:0.875333:0.927980:0.875333:0.927980:0.859550:0.519041:0.859550:0.012564:0.009827:0.004551:0.009827:0.004369:0.011188:0.008935:0.010326:0.011188:0.004369:0.012292:0.003024:0.010326:0.005866:0.005866:0.004385:0.003417:0.003417:0.004369:0.005579:0.005866:0.003024:0.003024:0.010175:0.009223:0.005125:0.004369:0.003024:0.003024:0.014182:0.003024:0.005125:0.010341:0.005125:0.003024:0.009903:0.009223:0.004369:0.009903:0.004747:0.004369:0.010311:0.009223:0.008104:0.005866:0.003024:0.009782:0.010326:0.003024:0.004385:0.010326:0.009782:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004385:0.007560:0.004188
comfortable at rest, but ordinary physical activity caus-:@0.519041:0.889279:0.923792:0.889279:0.923792:0.873497:0.519041:0.873497:0.009782:0.009903:0.014182:0.004747:0.009903:0.004551:0.005125:0.010326:0.010311:0.003024:0.009827:0.004369:0.010326:0.005125:0.004385:0.004551:0.009827:0.005866:0.005125:0.004188:0.004369:0.010311:0.009192:0.005125:0.004385:0.009903:0.004551:0.010357:0.003024:0.009223:0.010326:0.004551:0.008104:0.004385:0.010311:0.009223:0.008104:0.005866:0.003024:0.009782:0.010326:0.003024:0.004385:0.010326:0.009782:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004385:0.009782:0.010326:0.009192:0.005866:0.005020
es symptoms of heart failure). The primary endpoint was :@0.519041:0.903226:0.927996:0.903226:0.927996:0.887444:0.519041:0.887444:0.009827:0.005866:0.003886:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.003886:0.009903:0.004747:0.003886:0.009223:0.009827:0.010326:0.004551:0.005125:0.003886:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005579:0.004188:0.003886:0.006441:0.009223:0.009827:0.003886:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.003886:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.003886:0.012564:0.010326:0.005866:0.004188
the first event in the composite of cardiovascular death :@0.519041:0.917173:0.927996:0.917173:0.927996:0.901391:0.519041:0.901391:0.005125:0.009223:0.009827:0.004007:0.003681:0.003681:0.004551:0.005866:0.005125:0.004007:0.009827:0.008376:0.009827:0.009223:0.005125:0.004007:0.003024:0.009223:0.004007:0.005125:0.009223:0.009827:0.004007:0.009782:0.009903:0.014182:0.010311:0.009903:0.005866:0.003024:0.005125:0.009827:0.004007:0.009903:0.004747:0.004007:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004022:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188
or heart-failure hospitalisation.:@0.519041:0.931120:0.738116:0.931120:0.738116:0.915337:0.519041:0.915337:0.009903:0.004551:0.004188:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
The pharmaceutical agent Entresto , is currently pre-:@0.533328:0.945333:0.923806:0.945363:0.923806:0.929580:0.533328:0.929550:0.006441:0.009223:0.009827:0.005140:0.010311:0.009223:0.010326:0.004551:0.014182:0.010326:0.009782:0.009827:0.009192:0.005125:0.003024:0.009782:0.010326:0.003024:0.005156:0.010326:0.010175:0.009827:0.009223:0.005125:0.005140:0.008104:0.009223:0.005125:0.004551:0.009827:0.005866:0.005125:0.009903:0.006545:0.004188:0.005140:0.003024:0.005866:0.005156:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.005140:0.010311:0.004551:0.009827:-0.826570
®:@0.795653:0.940064:0.802203:0.940064:0.802203:0.930910:0.795653:0.930910:0.006550